Crown Agents, London, United Kingdom.
Asian Development Bank, Manila, Philippines.
Front Public Health. 2023 Mar 2;11:1143790. doi: 10.3389/fpubh.2023.1143790. eCollection 2023.
The ability to support a comprehensive vaccine research and development (R&D) portfolio from a health security perspective has taken on enhanced significance over the past 3 years whereby countries that had existing vaccine R&D infrastructure (G7, Russia and China) have been at the forefront of global efforts to combat COVID-19. Few countries outside of these key players have the infrastructure necessary to develop national vaccine programs, though this is beginning to change with investment across many low- and middle-income countries. These same opportunities exist for countries in Central and West Asia, and in this perspective, we highlight the existing infrastructure and expertise across seven countries (Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, and Uzbekistan) and propose opportunities for enhanced collaboration along with a bold proposal for establishing a new-build, regional vaccine translational research institute to facilitate the development of a robust, regional vaccine R&D environment to combat existing and future health challenges.
从卫生安全的角度来看，过去三年来，支持全面疫苗研发（R&D）组合的能力具有重要意义，因此，拥有现有疫苗研发基础设施的国家（七国集团、俄罗斯和中国）一直处于全球抗击 COVID-19 努力的前沿。除了这些关键参与者之外，很少有国家拥有必要的基础设施来制定国家疫苗计划，但随着许多中低收入国家的投资，这种情况开始发生变化。中东和西亚的国家也有同样的机会，在这方面，我们强调了七个国家（亚美尼亚、阿塞拜疆、格鲁吉亚、哈萨克斯坦、吉尔吉斯斯坦、塔吉克斯坦和乌兹别克斯坦）现有的基础设施和专业知识，并提出了加强合作的机会，以及建立一个新的、区域性疫苗转化研究机构的大胆建议，以促进建立一个强大的、区域性疫苗研发环境，以应对现有和未来的健康挑战。
